Lineage Cell Therapeutics Inc (LCTX)
1.13
-0.02 (-1.74%)
USD |
NYAM |
Sep 30, 16:00
1.145
+0.02 (+1.33%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 191.82M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -55.16% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 14.74 |
| Price to Book Value | 2.315 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 90.06% |
News
Headline
Wire
Time (ET)
Yahoo
08/15 08:00
MT Newswires
08/11 16:19
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Yahoo
08/11 16:05
Yahoo
08/04 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/10/2022* | -- | Results | Q3 2022 | -- | -0.04 | -- | |
| 11/10/2022* | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/11/2022 | -- | Results | Q2 2022 | -0.04 | -0.02 | -78.50% | |
| 08/11/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/12/2022 | -- | Results | Q1 2022 | -0.04 | -0.06 | 35.50% | |
| 05/12/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/10/2022 | -- | Results | Q4 2021 | -0.05 | -0.05 | 4.76% | |
| 03/10/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures. |
| URL | https://www.lineagecell.com |
| Investor Relations URL | https://investor.lineagecell.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Nov. 10, 2022 (est.) |
| Last Earnings Release | Aug. 11, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 30, 2022.
Fundamentals
| Revenue (TTM) | 12.95M |
| Total Expenses (TTM) | 58.66M |
| Net Income (TTM) | -50.66M |
| Total Assets (Quarterly) | 135.92M |
| Total Liabilities (Quarterly) | 54.42M |
| Shareholders Equity (Quarterly) | 82.85M |
| Cash from Operations (TTM) | 4.121M |
| Cash from Investing (TTM) | -0.357M |
| Cash from Financing (TTM) | 5.219M |
Ratings
Profile
Edit
| Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures. |
| URL | https://www.lineagecell.com |
| Investor Relations URL | https://investor.lineagecell.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Nov. 10, 2022 (est.) |
| Last Earnings Release | Aug. 11, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| LCTX Tweets |